KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $15.8 million.

  • Travere Therapeutics' Depreciation & Amortization (CF) rose 4047.51% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year increase of 3356.37%. This contributed to the annual value of $43.6 million for FY2024, which is 1304.18% up from last year.
  • As of Q3 2025, Travere Therapeutics' Depreciation & Amortization (CF) stood at $15.8 million, which was up 4047.51% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Depreciation & Amortization (CF) ranged from a high of $15.8 million in Q3 2025 and a low of -$7.8 million during Q4 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $8.3 million, with a median of $9.5 million in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 21791.04% in 2021, then soared by 154703.66% in 2023.
  • Travere Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at -$7.8 million in 2021, then skyrocketed by 180.71% to $6.3 million in 2022, then surged by 50.32% to $9.5 million in 2023, then rose by 27.43% to $12.1 million in 2024, then soared by 30.58% to $15.8 million in 2025.
  • Its Depreciation & Amortization (CF) was $15.8 million in Q3 2025, compared to $14.0 million in Q2 2025 and $12.8 million in Q1 2025.